RYAH Group (CSE: RYAH) CEO Dr. Dave Richards has released a report outlining key progress made during his first two months as CEO of the connected device and big data and technology company, which is focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. In the report, Richards notes that as a cofounder of the MIT Innovation Lab, he has seen many of the most innovative ideas and enterprises ever conceived, and when he was asked to lead RYAH, he worked to understand the business model and also to identify what issues needed to be corrected. He recognized how is experience and skills as a strategic innovation leader might help the company achieve its massive potential. “I empowered and strengthened the leadership team. I encouraged creative conflict and debate, leading to greater clarity on direction,” said RYAH CEO Dr. Dave Richards in the press release. “I engaged the team in developing a new sense of purpose, and in developing a strategic plan to drive success and value. I cut unnecessary costs, improved communications and focus on priorities, and operational effectiveness. . . . The bottom line is that the business needed some course changes, and we’re now on track to generate near-term revenues, profits, and returns on the investments that have been made based on faith in our mission, to empower decision-making, insights and innovations for a healthier future through our ecosystem of connected devices, applications and big data.”
To view the full press release, visit https://ibn.fm/kXbXo
About RYAH Group Inc.
RYAH is a big data and technology company enabling valuable AI-powered predictive analytics of the efficacy of plant-based medicines and other nutraceuticals administered through its range of innovative IoT-connected medical devices including inhalers, patches and pens. RYAH’s robust big data platform, the only one of its kind in this space, aggregates and analyzes HIPAA-compliant patient data, helping doctors and patients personalize treatments, control dosages, and better predict and monitor outcomes. Beyond specific medical uses, RYAH supports the use of a variety of nutraceuticals by users for wellness purposes, including personal enjoyment – i.e., recreational use. The collection and analyses of objective and subjective usage data, along with data derived through natural language processing of various scientific and other relevant literatures, will enable highly valuable insights for a wide variety of stakeholders, starting with the users themselves, and extending to clinicians, medical scientists, insurance providers, dispensaries, licensed growers, producers, pharmaceutical producers, and more. Through the above, a relentless focus on innovation, and track record of developing win-win collaborative partnerships within relevant industries, RYAH is continuously building a unique and highly valuable IP portfolio and big data assets ready to be monetized. For more information about the company, please visit www.RyahGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
